BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, BCR-ABL fusion protein 210 kDa is illustrated with 90% of CML, which induces malignant transformation through inhibition of cell adhesion, apoptosis, and differentiation [9].